Aquinox Pharma (AQXP) Appoints New Chief Medical Officer
- Apple (AAPL) Tops Q4 EPS by 2c; Issues Solid Outlook
- Wall Street slips on earnings; Apple falls late after results
- Chipotle Mexican Grill (CMG) Posts Q3 EPS of $0.27; Comps Miss Views; Additional Stock Buyback Approved
- Pandora (P) Misses Q3 EPS by 1c, Q4 Revenue Guidance Falls Short
- Panera Bread (PNRA) Tops Q3 EPS by 3c; Raises Outlook
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Aquinox Pharmaceuticals, Inc. (Nasdaq: AQXP) announced the appointment of Dr. Barbara Troupin, M.D. as Chief Medical Officer and Vice President, Clinical Development. Dr. Troupin will lead overall clinical and medical affairs strategies for Aquinox’s ongoing programs as well as future development and potential commercialization plans.
Over more than 18 years Dr. Troupin has led clinical development and strategy at multiple, leading clinical research institutions and within the therapeutic drug development sector. Dr. Troupin most recently served as Senior Vice President and Chief Medical Officer at Apricus Bioscience, Inc. where she led the development and execution of clinical strategy for three drug development programs ranging from proof-of-concept to NDA filing, including Vitaros for the treatment of erectile dysfunction. Prior to Apricus, Dr. Troupin held the role of Vice President in Medical Affairs at VIVUS, Inc. where she led risk evaluation and mitigation strategy for Qsymia to treat weight loss, while also building relationships with thought leaders and key opinion leaders (KOLs). Dr. Troupin received her Doctorate in Medicine in 1995 from the University of Pennsylvania School of Medicine where she also completed her Master’s in Business Administration, with an emphasis in health care management, from the Wharton School of Business.
“Barbara brings a proven track record of building KOL and patient advocacy relationships, defending regulatory submissions, and overall success in clinical strategy,” said David Main, President & CEO of Aquinox. “Barbara joins at an ideal time for contributing medical and clinical leadership to our recently initiated Leadership 301 phase 3 clinical trial with AQX-1125 in Interstitial Cystitis/Bladder Pain syndrome (IC/BPS) as well as for guiding our clinical expansion and supporting our potential partnering and commercial preparations.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Diplomat Pharmacy (DPLO) CFO Sean Whelan to Step Down; Paul Urick Promoted to President
- Aerojet Rocketdyne (AJRD) Taps United Tech's Lundstrom as CFO
- PRGX Global (PRGX) to Acquire SaaS P2P SIM Service Provider Lavante
Create E-mail Alert Related CategoriesManagement Changes, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!